John Leonard, Intellia Therapeutics CEO
March 2, 2023 10:50 AM ESTUpdated March 3, 02:52 PM
R&D

In­tel­lia gets FDA clear­ance to start hered­i­tary an­gioede­ma gene edit­ing tri­al in US

Lei Lei Wu

News Reporter

In­tel­lia Ther­a­peu­tics an­nounced Thurs­day morn­ing that the FDA cleared it to test a gene edit­ing ther­a­py for hered­i­tary an­gioede­ma (HAE) in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times